All Stories

  1. Non-pharmacological interventions modulating immune response in Parkinson's disease: where do we stand for future preventive approaches
  2. Expanding the phenotypic spectrum of SOD1‑related ALS: upper motor neuron predominance in a p.D91A case
  3. Sex Differences in Levodopa‐Sparing Effect of Safinamide: Post‐hoc Findings from a Multicenter, Longitudinal, Case‐Control Study
  4. Genetic Prognostic Factors in Multiple Sclerosis: Key Discoveries and Unmet Needs
  5. Mitochondrial Dysfunction: The Cellular Bridge from Emotional Stress to Disease Onset: A Narrative Review
  6. Profiling cognition and brain metabolism in amyotrophic lateral sclerosis and frontotemporal dementia
  7. “Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson’s disease”
  8. CD4+ T-cell transcription factors as early predictors of phenoconversion in idiopathic rapid eye movement sleep behaviour disorder
  9. The Association of Axonal Damage Biomarkers and Osteopontin at Diagnosis Could Be Useful in Newly Diagnosed MS Patients
  10. The importance of early biomarkers in the identification of neurodegenerative disorders
  11. Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation‐Wide, Multicenter, Longitudinal, “Real‐World” Study. The EPIC Study
  12. Neutrophil-to-Lymphocyte Ratio in the Alzheimer’s Disease Continuum
  13. Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis
  14. IMMUnity Unveiled: A Translational NETwork for tackling PARKinson's Disease – IMMUPARKNET
  15. Biomarkers of Intrathecal Synthesis May Be Associated with Cognitive Impairment at MS Diagnosis
  16. Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis—A real-world evidence study
  17. (Dys)regulation of the Immune System in Parkinson’s Disease: Methodologies, Techniques, and Key Findings from Human Studies
  18. Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis
  19. A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis
  20. CD4+ T-cell transcription factors predict phenoconversion in idiopathic rapid eye movement sleep behavior disorder
  21. Family History in Parkinson's Disease: A National Cross‐Sectional Study
  22. Coupling motor evoked potentials and brain [18F]FDG-PET in Amyotrophic Lateral Sclerosis: preliminary findings on disease severity
  23. Deterioration of people with Parkinson’s symptoms during COVID-19 lockdown: results of a web-based survey in Northwestern Italy
  24. From Mild Cognitive Impairment to Dementia: The Impact of Comorbid Conditions on Disease Conversion
  25. Polymorphisms in the Dopaminergic Receptor D3 Gene Correlate with Disease Progression Rate in Relapsing–Remitting Multiple Sclerosis Patients
  26. The Role of Diet in Multiple Sclerosis Onset: A Prospective Study Using UK Biobank
  27. Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond
  28. Lifestyle Modulators of Neuroplasticity in Parkinson’s Disease: Evidence in Human Neuroimaging Studies
  29. New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives
  30. Gas6/TAM system as potential biomarker for multiple sclerosis prognosis
  31. Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson’s Disease
  32. Serum and cerebrospinal fluid neurofilament light chains measured by SIMOA™, Ella™, and Lumipulse™ in multiple sclerosis naïve patients.
  33. Menstrual‐Related Fluctuations in a Juvenile‐Onset Parkinson's Disease Patient Treated with STN‐DBS: Correlation with Local Field Potentials
  34. Variability in Clinical Phenotype in TARDBP Mutations: Amyotrophic Lateral Sclerosis Case Description and Literature Review
  35. Circulating Extracellular Vesicles in Subarachnoid Hemorrhage Patients: Characterization and Cellular Effects
  36. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
  37. Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy
  38. Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy
  39. Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants
  40. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
  41. Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment
  42. Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells
  43. A novel GRN mutation in an Italian patient with non-fluent variant of primary progressive aphasia at onset: a longitudinal case report
  44. Meet the Co-Editor
  45. Isolated Myelopathy in Occult Breast Carcinoma with Negative Paraneoplastic Antibodies: A Case Report of a Rare Condition
  46. The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease
  47. Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis
  48. Relationship between [123I]FP-CIT SPECT data and peripheral CD4 + T cell profile in newly-diagnosed drug-naïve Parkinson’s disease patients
  49. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  50. Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis
  51. The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of Proteomics
  52. Neuroimaging in multiple system atrophy
  53. Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
  54. Biomarkers in multiple sclerosis
  55. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
  56. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature
  57. Visuospatial Deficits are associated with Pisa Syndrome and not Camptocormia in Parkinson's disease
  58. T Lymphocytes in Parkinson’s Disease
  59. Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio Are Associated with Mild Cognitive Impairment in Parkinson’s Disease: A Single-Center Longitudinal Study
  60. PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability
  61. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
  62. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications
  63. A very early onset of juvenile parkinsonism
  64. The Effects of COVID-19-Related Restrictions on Parkinson’s Disease Patients in Italy: Results of a Structured Survey
  65. Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient
  66. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study
  67. Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction
  68. The Role of Tau beyond Alzheimer’s Disease: A Narrative Review
  69. Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know?
  70. The Immune System as a Therapeutic Target for Old and New Drugs in Parkinson’s Disease
  71. Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression
  72. Meet the Editorial Board Member
  73. Oxidative Stress in Non-Alcoholic Fatty Liver Disease
  74. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
  75. Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis
  76. Susac Syndrome: an uncommon cause of impaired vision
  77. Did the role of the neurologist in the emergency department change during the COVID-19 pandemic? Evidence from an Italian nationwide survey
  78. Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population
  79. Is There any Link between Madelung Disease and Ischemic Stroke? A Case Report
  80. Clinical relevance of single-subject brain metabolism patterns in amyotrophic lateral sclerosis mutation carriers
  81. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
  82. Why searching for Anti-Contactin-1 antibodies in chronic inflammatory demyelinating polyneuropathy: a case report.
  83. Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients
  84. Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson’s disease patient
  85. Guillain–Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report
  86. Increased Prevalence of Neuropsychiatric Disorders during COVID-19 Pandemic in People Needing a Non-Deferrable Neurological Evaluation
  87. Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis
  88. An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients
  89. CSF Tau protein correlates with cognitive impairment in multiple sclerosis patients at diagnosis
  90. Neuromyelitis optica with syringomyelia: A case report and neurosonological follow up
  91. A challenging diagnosis of neurodegenerative dementia: Psychiatric onset of frontotemporal lobar degeneration
  92. The impact of COVID-19 pandemic on cognition of people with dementia
  93. The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease
  94. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
  95. Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19
  96. The Impact of the COVID-19 Pandemic on the Cognition of People with Dementia
  97. Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease
  98. Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives
  99. Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians
  100. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
  101. Paraneoplastic neuromyelitis optica spectrum disorders: a case series
  102. Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series
  103. The Yin-Yang of osteopontin in nervous system diseases: damage versus repair
  104. Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study
  105. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients
  106. Intrathecal kappa free light chains as markers for multiple sclerosis
  107. Genetic parkinsonisms and cancer: a systematic review and meta-analysis
  108. Change over time of COVID-19 hospital presentation in Northern Italy
  109. Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson’s disease
  110. Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension
  111. CD4 + T‐Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson’s Disease
  112. Cortical visuomotor interactions in Freezing of Gait: A TMS approach
  113. Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  114. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  115. Meet Our Editorial Board Member
  116. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients
  117. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  118. Vogt-Koyanagi-Harada Syndrome: A Case of Bilateral Steroid-Responsive Loss of Vision
  119. Editorial: Peripheral Immunity in Parkinson's Disease: Emerging Role and Novel Target for Therapeutics
  120. Meet Our Editorial Board Member
  121. Meet Our Editorial Board Member
  122. TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration
  123. The vermiform appendix in Parkinson's disease: At the crossroad of peripheral immunity, the nervous system and the intestinal microbiome
  124. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  125. FRI0258 ANTI-RO/SSA POSITIVITY, ANTI-AQUAPORIN4 ANTIBODIES AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: A RETROSPECTIVE STUDY ON A CONTROVERSIAL CORRELATION
  126. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence
  127. Kappa free light chains could predict early disease course in multiple sclerosis
  128. Meet Our Editorial Board Member
  129. K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up
  130. Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis
  131. Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature
  132. Ultrasonography Monitoring of Optic Nerve Sheath Diameter and Retinal Vessels in Patients with Cerebral Hemorrhage
  133. Post-lumbar puncture headache: an adverse effect in multiple sclerosis work-up
  134. Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease
  135. Beta2-Adrenoceptor Agonists in Parkinson’s Disease and Other Synucleinopathies
  136. Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
  137. The Italian multiple sclerosis register
  138. LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients
  139. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  140. CSF biomarkers of neurodegeration in early multiple sclerosis course
  141. Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients
  142. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  143. Chronic obstructive pulmonary disease may complicate Alzheimer’s disease: a comorbidity problem
  144. MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis
  145. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  146. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  147. Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from Multiple Sclerosis patients: potential biomarkers of disease susceptibility and progression
  148. O158 Excessive inhibitory visuomotor connections in parkinson’s disease with freezing of gait
  149. A patient with autoimmune limb-girdle myasthenia, and a brief review of this treatable condition.
  150. Peripheral neuropathy as marker of severe Parkinson's disease phenotype
  151. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
  152. The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study)
  153. Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
  154. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis
  155. Prevalence and burden of dysautonomia in advanced Parkinson's disease
  156. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
  157. Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs
  158. Insights into the protective role of immunity in neurodegenerative disease
  159. Longitudinal Assessment of Transorbital Sonography, Visual Acuity, and Biomarkers for Inflammation and Axonal Injury in Optic Neuritis
  160. Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis
  161. Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease
  162. Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson’s Disease
  163. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson’s patients
  164. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia
  165. D NAJC 6 Mutations Associated With Early-Onset Parkinson's Disease
  166. Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations in Italian Parkinson's disease patients
  167. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases
  168. Thrombin Cleavage of Osteopontin Modulates Its Activities in Human CellsIn Vitroand Mouse Experimental Autoimmune EncephalomyelitisIn Vivo
  169. Impaired visual inhibition in migraine with aura
  170. MRI imaging and clinical features of sciatic nerve injection injury
  171. Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies
  172. Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy
  173. Predicting Cognitive Decline in Parkinson’s Disease: Can We Ask the Genes?
  174. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis
  175. Intensive Rehabilitation Treatment in Early Parkinson’s Disease
  176. Transorbital Sonography in Acute Optic Neuritis: A Case-Control Study
  177. Joint Congress of European Neurology 31 May–3 June 2014 Istanbul, Turkey
  178. Advances in Neuroimmunology: From Bench to Bedside
  179. Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis
  180. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
  181. Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage
  182. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations
  183. Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonism†
  184. Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients
  185. Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome
  186. Defining the Epsilon-Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonus-Dystonia: A Reappraisal of Genetic Testing Criteria
  187. Robotic gait training is not superior to conventional treadmill training in Parkinson's Disease: A single-blind randomized controlled trial
  188. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease
  189. The role of T cell apoptosis in nervous system autoimmunity
  190. Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease
  191. Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments
  192. Robotic Gait Training Is not Superior to Conventional Treadmill Training in Parkinson Disease
  193. The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function
  194. The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression
  195. Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers
  196. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis
  197. Effectiveness of Intensive Inpatient Rehabilitation Treatment on Disease Progression in Parkinsonian Patients
  198. The Role of Osteopontin in Neurodegenerative Diseases
  199. Fas-mediated T-cell apoptosis in chronic inflammatory demyelinating polyneuropathy
  200. GSK3β genetic variability in patients with Multiple Sclerosis
  201. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option
  202. Complex pattern of convulsive syncope in glossopharyngeal neuralgia: Video/EEG report and short review
  203. Levodopa‐induced belly dancer's dyskinesias in Parkinson's disease: Report of one case
  204. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature
  205. Signals of Apoptotic Pathways in Several Types of Meningioma
  206. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males
  207. Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline
  208. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease
  209. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy
  210. FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β
  211. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP
  212. Complex movement disorders in primary antiphospholipid syndrome: A case report
  213. Spontaneous Intracranial Hypotension Presenting as a Reversible Dorsal Midbrain Syndrome
  214. Variations of the perforin gene in patients with multiple sclerosis
  215. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis
  216. MDC/CCL22 intrathecal levels in patients with multiple sclerosis
  217. Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis
  218. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution
  219. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course
  220. ICOS cooperates with CD28, IL-2, and IFN-γ and modulates activation of human naïve CD4+ T cells
  221. Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy
  222. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis
  223. E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis
  224. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression
  225. Cutaneous silent period in human immunodeficiency virus-related peripheral neuropathy
  226. Abnormal response to glutamate of T lymphocytes from multiple sclerosis patients
  227. Diagnosis of psychogenic paralysis: The role of motor evoked potentials
  228. Anticonvulsvant Drugs and Cognitive Functions in Elderly Patients with Epilepsy
  229. Anticonvulsant Drugs and Cognitive Functions in Elderly Patients with Epilepsy
  230. Defective T cell Fas function in patients with multiple sclerosis
  231. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer